Please login to the form below

cancer vaccine

This page shows the latest cancer vaccine news and features for those working in and with pharma, biotech and healthcare.

Newly-listed BioNTech buys Neon to boost cell therapy assets

BioNTech has agreed to pay $67m for Cambridge, Massachusetts-based Neon, which ended 2019 on a sour note by dropping its clinical-stage personalised cancer vaccine NEO-PV-01 after disappointing ... Also in the pipeline is NEO-STC-01, another RAS-targeted

Latest news

Merck strengthens KRAS stake with Taiho and Astex partnership

At MSD we continue to pursue new regimens designed to extend the benefits of highly selective therapies to more patients with cancer,” said Roger Perlmutter (pictured left), president, MSD Research Laboratories. ... Merck also has an ongoing
Merck CFO: we’re not only about Keytruda

He said the performance of other cancer drugs like Lenvima (lenvatinib) and Lynparza (olaparib), revenue from which doubled in the quarter – as well as the vaccine portfolio headed by cervical cancer ... vaccine Gardasil and HIV franchise – is
GSK eyes follow-up HPV vaccine

Cervarix from the US market after finding it was not competitive against rival Merck &Co’s HPV vaccine. ... Innovax has already developed a cervical cancer vaccine, Cecolin, which is HPV 16 &18 bivalent – these two HPV types are known to cause at
Boehringer’s head of pharma heads for the exit

Carine Bruillon. Recent deals have included a 325m acquisition of AMAL Therapeutics to gain access to its cancer vaccine technology, a $226m alliance with UK-listed biotech PureTech Health to develop ... a new approach to cancer immunotherapy, a 1.1bn
Boehringer posts solid first half as business revamp beds in

Last month for example it signed a 325m deal to acquire AMAL Therapeutics to gain access to its cancer vaccine technology, and in April forged a $226m alliance with UK-listed ... biotech PureTech Health to develop a new approach to cancer immunotherapy.

More from news
Approximately 2 fully matching, plus 147 partially matching documents found.

Latest Intelligence

Biotech profile: Tom Evans, CEO, Vaccitech.

You have a broad pipeline of candidates, including therapeutic vaccines, such as your vaccine for prostate cancer in phase 1. ... How big a role do you think therapeutic vaccines will play in future cancer treatment?
Pharma deals in August 2015

This was the fifth deal announced by AstraZeneca/Medimmune in the month under which the company gained access to INO-3112 a cancer vaccine which targets cancers caused by human papilloma ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐3112
Pharma deals in March 2015

The companies will collaborate to develop three anti-cancer drugs, one Mab from Lilly and a Mab and an additional molecule from Innovent. ... This is what BMS has secured with Bavarian Nordic's cancer vaccine targeting PSA in phase III for treatment of
Pharma deals in February 2015

This month saw the deadline, highlighted in January's Deal Watch, for Valeant to acquire Dendreon, and more specifically the dendritic cell, prostate cancer vaccine Provenge (sipuleucel-T), come and go.
Deal Watch table for November 2013

R&D and. commercialisation. IMA942 tumour-associated peptide cancer vaccine candidates in NSCLC and prostate cancer. ... BeiGene / Merck. Serono. Co-development. Expansion of collaboration to include BeiGene 290 for cancer.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

Dendreon appoints new R&D lead

Cancer vaccine company Dendreon has added to its senior team, appointing Dr Bruce Brown as its new senior vice president, medical. ... stage prostate cancer, with the hope of curing more men of the disease.”.
Vaccibody name Martin Bonde as CEO

He joins from EpiTherapeutics where he holds the same role. Norwegian cancer vaccine company Vaccibody has appointed Dr Martin Bonde as CEO, effective from August 10.
Dendreon CEO to step down

The decision comes as Dendreon continues to struggle as its only product Provenge – a 'vaccine' for prostate cancer ' – fails to live up to high expectations. ... a personalised cancer treatment.
AP Pharma appoints Dendreon’s Jesse Hollingsworth to lead sales

prostate cancer vaccine Provenge.
Lindsay Rocco to lead corporate communications at Dendreon

The US biotech, which markets prostate cancer vaccine Provenge (sipuleucel-T), said Rocco will be responsible for all communications functions of the company, reporting directly to chair, president and CEO John ... Lindsay is a seasoned communicator with

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

Secondary effects of COVID-19 on the healthcare system and patients

To date, most of the focus has understandably been on the immediate effects of the virus and the efforts to enforce physical distancing and develop a vaccine.
Understanding the "Big Picture"

A good example of this is Globocan cancer epidemiology data, which is extremely high level but does not provide insight as to staging or treatment rates. ... A good example of this “Risk-awareness thinking” would be the impact of the cervical cancer

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....